---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000018"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:58:10.449764+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance

## Summary
- Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).
- Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).
- Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.
- Company reaffirms 2025 full-year guidance.

## SEC filing metadata
- accession: 0001723128-25-000018
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/0001723128-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/amrx-20250502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000018
- JSON: https://secwatch.observer/filing/0001723128-25-000018.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.